logo image
search icon
Botulinum Toxin in Urology Market

Botulinum Toxin in Urology Market Size, Share & Trends Analysis Report By Application (Overactive Bladder, Neurogenic Detrusor Overactivity), By End-use (Hospitals, Urology Clinics), By Region, And By Segment Forecasts, 2023-2031.

Report ID : 2255 | Published : 2023-12-05 | Pages: 180 | Format: PDF/EXCEL

Botulinum Toxin in Urology Market Size is valued at USD 903.82 Mn in 2022 and is predicted to reach USD 1,504.89 Mn by the year 2031 at a 5.94% CAGR during the forecast period for 2023-2031.

Botulinum Toxin in Urology Market

Botulinum toxin, commonly known as Botox, has found applications in the field of urology for the treatment of various medical conditions, particularly those related to the lower urinary tract. A range of significant factors drives the growth of the botulinum toxin in the urology market. One of the primary catalysts is the increasing prevalence of urological disorders on a global scale. As conventional treatments exhibit limitations, there has been a surge in demand for alternative solutions, with botulinum toxin emerging as a preferred option due to its muscle-relaxing properties. Moreover, the minimally invasive nature of Botox injections has made a considerable contribution to market expansion. Patients are increasingly choosing these procedures due to their low risk, minimal discomfort, and quicker recovery times compared to traditional surgical interventions. 

Furthermore, the effectiveness of botulinum toxin in alleviating symptoms associated with bladder dysfunction has gained widespread recognition. Positive patient outcomes and increased satisfaction levels have stimulated market growth, encouraging patients and healthcare providers to adopt this innovative approach. With ongoing advancements in research and development leading to improved formulations and delivery methods, it is anticipated that the botulinum toxin in the urology market will experience sustained growth, ultimately enhancing the quality of life for individuals coping with urological disorders.

Competitive Landscape

Some Major Key Players In The Botulinum Toxin in Urology Market:

  • AbbVie Inc.
  • Merz Pharma
  • Ipsen Pharma
  • GALDERMA
  • Allergan PLC
  • Sun Pharmaceutical Industries Lt
  • Biosensor Healthcare Pvt Ltd
  • Others

Market Segmentation:

The botulinum toxin in the urology market includes End-Use and application. The application segment is segmented as overactive bladder and neurogenic detrusor overactivity. According to the End-Use segment, the market is divided into hospitals and urology clinics.

Based On The Application, The Overactive Bladder Segment Is A Major Contributor To The Botulinum Toxin In The Urology Market. 

The overactive bladder category is expected to hold a major share of the global botulinum toxin in the urology market in 2022. Overactive bladder, characterized by a sudden and involuntary contraction of the bladder muscles, leads to frequent and urgent urination, often accompanied by urinary incontinence. Neurogenic Detrusor Overactivity, a condition commonly associated with spinal cord injuries or neurological disorders, results in uncontrolled bladder contractions and urinary urgency. Botulinum toxin, specifically Botox, has emerged as a revolutionary therapeutic option for patients suffering from these conditions. By targeting the underlying cause of these disorders - abnormal muscle contractions - botulinum toxin injections effectively relax the bladder muscles. 

The Hospital Segment Witnessed A Rapid Growth.

The segment, hospital, is estimated to grow rapidly in the global botulinum toxin market. Hospitals play a pivotal role as essential healthcare institutions, acting as central hubs for the diagnosis and management of intricate medical conditions, which include urological disorders. Incorporating botulinum toxin therapies within the hospital environment exemplifies the contemporary healthcare approach, which is comprehensive and interdisciplinary. Individuals dealing with conditions like overactive Bladder (OAB) and neurogenic detrusor overactivity (NDO) frequently seek specialized care within hospital facilities. In these settings, proficient urologists and healthcare experts administer botulinum toxin injections with precision and expertise. The structured and closely monitored hospital environment ensures that patients receive treatments that are not only secure but also highly effective. 

In The Region, The North American Botulinum Toxin In The Urology Market Holds A Significant Revenue Share.

The North American botulinum toxin in the urology market is expected to record the maximum market share. In North America, specifically in the United States and Canada, the market stands out for its vigorous research and development initiatives, sophisticated healthcare infrastructure, and a significant incidence of urological disorders. Substantial clinical trials and partnerships between pharmaceutical companies and research institutions stimulate innovation, positioning North America as a prominent centre for the utilization of botulinum toxin in urological applications. Furthermore, established reimbursement policies and a heightened level of awareness among both patients as well as healthcare professionals play pivotal roles in promoting the extensive uptake of these treatments.

In addition, Asia Pacific is likely to grow at a rapid rate in the global botulinum toxin in the urology market. The Asia-Pacific region is emerging as a prospective market for the use of botulinum toxin in urology. This growth is credited to the increasing occurrence of urological disorders, rising healthcare investments, and a growing awareness of advanced treatment alternatives. Nations like China, Japan, and India are experiencing a notable uptick in demand for progressive therapies, including botulinum toxin treatments, in response to the healthcare requirements of their ageing populations. 

Recent Developments:

  • In February 2021, Allergan, a subsidiary of AbbVie, has received approval from the U.S. FDA for the use of BOTOX® in the treatment of detrusor overactivity (bladder muscle overactivity) linked to a neurologic condition in pediatric patients aged five years and above who have not responded well to or cannot tolerate anticholinergic medication. 

Botulinum Toxin in Urology Market Report Scope

Report Attribute

Specifications

Market Size Value In 2022

USD 903.82 Mn

Revenue Forecast In 2031

USD 1,504.89 Mn

Growth Rate CAGR

CAGR of 5.94 % from 2023 to 2031

Quantitative Units

Representation of revenue in US$ Million and CAGR from 2023 to 2031

Historic Year

2019 to 2022

Forecast Year

2023-2031

Report Coverage

The forecast of revenue, the position of the company, the competitive market structure, growth prospects, and trends

Segments Covered

By Application and End-Use

Regional Scope

North America; Europe; Asia Pacific; Latin America; Middle East & Africa

Country Scope

U.S.; Canada; U.K.; Germany; China; India; Japan; Brazil; Mexico; The UK; France; Italy; Spain; China; Japan; India; South Korea; Southeast Asia; South Korea; Southeast Asia

Competitive Landscape

AbbVie Inc., Merz Pharma; Ipsen Pharma; GALDERMA; Allergan PLC; Sun Pharmaceutical Industries Ltd.; Biovencer Healthcare Pvt Ltd.

Customization Scope

Free customization report with the procurement of the report and modifications to the regional and segment scope. Particular Geographic competitive landscape.

Pricing And Available Payment Methods

Explore pricing alternatives that are customized to your particular study requirements.

Chapter 1. Methodology and Scope

1.1. Research Methodology

1.2. Research Scope & Assumptions

Chapter 2. Executive Summary

Chapter 3. Global Botulinum Toxin In Urology Market Snapshot

Chapter 4. Global Botulinum Toxin In Urology Market Variables, Trends & Scope

4.1. Market Segmentation & Scope

4.2. Drivers

4.3. Challenges

4.4. Trends

4.5. Investment and Funding Analysis

4.6. Industry Analysis – Porter’s Five Forces Analysis

4.7. Competitive Landscape & Market Share Analysis

4.8. Impact of Covid-19 Analysis

Chapter 5. Market Segmentation 1: By Application Estimates & Trend Analysis

5.1. By Application, & Market Share, 2020 & 2031

5.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2020 to 2031 for the following By Application:

5.2.1. Overactive Bladder

5.2.2. Neurogenic Detrusor Overactivity

Chapter 6. Market Segmentation 2: By End-User Estimates & Trend Analysis

6.1. By End-User & Market Share, 2020 & 2031

6.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2020 to 2031 for the following By End-User:

6.2.1. Hospitals

6.2.2. Urology Clinics

Chapter 7. Botulinum Toxin In Urology Market Segmentation 3: Regional Estimates & Trend Analysis

7.1. North America

7.1.1. North America Botulinum Toxin In Urology Market revenue (US$ Million) estimates and forecasts By Application, 2019-2031

7.1.2. North America Botulinum Toxin In Urology Market revenue (US$ Million) estimates and forecasts By End-User, 2019-2031

7.1.3. North America Botulinum Toxin In Urology Market revenue (US$ Million) estimates and forecasts by country, 2019-2031

7.2. Europe

7.2.1. Europe Botulinum Toxin In Urology Market revenue (US$ Million) By Application, 2019-2031

7.2.2. Europe Botulinum Toxin In Urology Market revenue (US$ Million) By End-User, 2019-2031

7.2.3. Europe Botulinum Toxin In Urology Market revenue (US$ Million) by country, 2019-2031

7.3. Asia Pacific

7.3.1. Asia Pacific Botulinum Toxin In Urology Market revenue (US$ Million) By Application, 2019-2031

7.3.2. Asia Pacific Botulinum Toxin In Urology Market revenue (US$ Million) By End-User, 2019-2031

7.3.3. Asia Pacific Botulinum Toxin In Urology Market revenue (US$ Million) by country, 2019-2031

7.4. Latin America

7.4.1. Latin America Botulinum Toxin In Urology Market revenue (US$ Million) By Application, (US$ Million) 2019-2031

7.4.2. Latin America Botulinum Toxin In Urology Market revenue (US$ Million) By End-User, (US$ Million) 2019-2031

7.4.3. Latin America Botulinum Toxin In Urology Market revenue (US$ Million) by country, 2019-2031

7.5. Middle East & Africa

7.5.1. Middle East & Africa Botulinum Toxin In Urology Market revenue (US$ Million) By Application, (US$ Million) 2019-2031

7.5.2. Middle East & Africa Botulinum Toxin In Urology Market revenue (US$ Million) By End-User, (US$ Million) 2019-2031

7.5.3. Middle East & Africa Botulinum Toxin In Urology Market revenue (US$ Million) by country, 2019-2031

Chapter 8. Competitive Landscape

8.1. Major Mergers and Acquisitions/Strategic Alliances

8.2. Company Profiles

8.2.1. AbbVie Inc.

8.2.2. Merz Pharma

8.2.3. Ipsen Pharma

8.2.4. GALDERMA

8.2.5. Allergan PLC

8.2.6. Sun Pharmaceutical Industries Ltd.

8.2.7. Biovencer Healthcare Pvt Ltd

Segmentation Of Botulinum Toxin In Urology Market-

Botulinum Toxin In Urology Market By Application

  • Overactive Bladder
  • Neurogenic Detrusor Overactivity

Botulinum Toxin in Urology Market Seg

Botulinum Toxin In Urology Market By End-Use

  • Hospitals
  • Urology Clinics

Botulinum Toxin In Urology Market By Region-

North America-

  • The US
  • Canada
  • Mexico

Europe-

  • Germany
  • The UK
  • France
  • Italy
  • Spain
  • Rest of Europe

Asia-Pacific-

  • China
  • Japan
  • India
  • South Korea
  • South East Asia
  • Rest of Asia Pacific

Latin America-

  • Brazil
  • Argentina
  • Rest of Latin America

 Middle East & Africa-

  • GCC Countries
  • South Africa
  • Rest of Middle East and Africa

InsightAce Analytic follows a standard and comprehensive market research methodology focused on offering the most accurate and precise market insights. The methods followed for all our market research studies include three significant steps – primary research, secondary research, and data modeling and analysis - to derive the current market size and forecast it over the forecast period. In this study, these three steps were used iteratively to generate valid data points (minimum deviation), which were cross-validated through multiple approaches mentioned below in the data modeling section.

Through secondary research methods, information on the market under study, its peer, and the parent market was collected. This information was then entered into data models. The resulted data points and insights were then validated by primary participants.

Based on additional insights from these primary participants, more directional efforts were put into doing secondary research and optimize data models. This process was repeated till all data models used in the study produced similar results (with minimum deviation). This way, this iterative process was able to generate the most accurate market numbers and qualitative insights.

Secondary research

The secondary research sources that are typically mentioned to include, but are not limited to:

  • Company websites, financial reports, annual reports, investor presentations, broker reports, and SEC filings.
  • External and internal proprietary databases, regulatory databases, and relevant patent analysis
  • Statistical databases, National government documents, and market reports
  • Press releases, news articles, and webcasts specific to the companies operating in the market

The paid sources for secondary research like Factiva, OneSource, Hoovers, and Statista

Primary Research:

Primary research involves telephonic interviews, e-mail interactions, as well as face-to-face interviews for each market, category, segment, and subsegment across geographies

The contributors who typically take part in such a course include, but are not limited to: 

  • Industry participants: CEOs, CBO, CMO, VPs, marketing/ type managers, corporate strategy managers, and national sales managers, technical personnel, purchasing managers, resellers, and distributors.
  • Outside experts: Valuation experts, Investment bankers, research analysts specializing in specific markets
  • Key opinion leaders (KOLs) specializing in unique areas corresponding to various industry verticals
  • End-users: Vary mainly depending upon the market

Data Modeling and Analysis:

In the iterative process (mentioned above), data models received inputs from primary as well as secondary sources. But analysts working on these models were the key. They used their extensive knowledge and experience about industry and topic to make changes and fine-tuning these models as per the product/service under study.

The standard data models used while studying this market were the top-down and bottom-up approaches and the company shares analysis model. However, other methods were also used along with these – which were specific to the industry and product/service under study.

To know more about the research methodology used for this study, kindly contact us/click here.

user icon
office icon
mail icon
call icon

This website is secure, and we do not share your personal information with any third party. Privacy Policy

Need Customization
Need specific information/chapter from the report of the custom data table, graph or complete report? Tell us more.

Frequently Asked Questions

How big is the Botulinum Toxin in Urology Market?

Botulinum Toxin in Urology Market expected to grow at a 5.94% CAGR during the forecast period for 2023-2031.

Merz Pharma; Ipsen Pharma; GALDERMA; Allergan PLC; Sun Pharmaceutical Industries Ltd.; Biovencer Healthcare Pvt Ltd.

Our Clients

  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo

Media Citations

  • media citation logo
  • media citation logo
  • media citation logo
  • media citation logo
  • media citation logo
  • media citation logo
  • media citation logo
  • media citation logo
  • media citation logo

Growth opportunities and latent adjacency in Pharmaceuticals

Select Licence Type
$4456
$7786
$10000
$1200
Get Your GTM Strategy

Navigate market entry with channel selection, launch strategy & timeline, and pricing model support.

Equip yourself with the insights needed to develop a winning go-to-market strategy

Get real-time updates and joint control over project direction with our collaborative approach